{
  "nccn_ovariancancer_v3_2025__v00000000|18": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 18,
    "text": "Version 3.2025, 07/16/25 © 2025 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nClear Cell Carcinoma of the Ovary\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nClear cell carcinoma\nof the ovaryg,h,i\nStage\nIC2– IC3\nStage IA\nIB, IC1\nStage II–IV\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nIV platinum-based therapy\n(see primary regimens for stage I disease\n[OV-C, 5 of 12])\nor\nObserveg\nSystemic therapy\n(OV-C, 6 of 12)\nLCOC-3\nPATHOLOGIC\nDIAGNOSISa\nADJUVANT TREATMENTf\nMONITORING/\nFOLLOW-UP\nMonitoring/Follow-up\n(including tumor testing)\nand\nRecurrence therapyj\n(OV-6)\nIf known BRCA1/2\nmutation, consider\nmaintenance therapy\n(post-primary therapy)\n(OV-5)\na WHO Histologic Classification (OV-E).\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).",
    "metadata": {
      "rank": 1,
      "score": 0.6360728740692139
    },
    "cached_at": "2026-01-19T08:46:02.356347"
  },
  "esmo_cpg_epithelialovarian_2023__v00000000|10": {
    "doc_id": "esmo_cpg_epithelialovarian_2023__v00000000",
    "page": 10,
    "text": "with ﬁrst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciﬁcally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.",
    "metadata": {
      "rank": 2,
      "score": 0.6341652274131775
    },
    "cached_at": "2026-01-19T08:46:02.358256"
  },
  "esmo_cpg_epithelialovarian_2023__v00000000|11": {
    "doc_id": "esmo_cpg_epithelialovarian_2023__v00000000",
    "page": 11,
    "text": "cytoreduction\no Residual ChT toxicity\no The patient’s general condition and preferences\n\u0004 Patients with ﬁrst relapse of ovarian cancer after >6\nmonths of last platinum administration should be evalu-\nated by a gynaecological oncology centre experienced in\nsurgery for ovarian cancer to identify potential candi-\ndates for surgical cytoreduction [I, A].\n\u0004 Patients who have previously responded to platinum\nwithout early symptomatic relapse should be treated\nwith either a platinum-based doublet (PLD, gemcitabine\nor paclitaxel) with bevacizumab [I, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3]\nor a platinum-based doublet followed by maintenance\nwith PARPi therapy if a response is achieved and the\npatient has not been previously exposed to PARPis\n[I, A; olaparib for BRCA1/2-mutated: ESMO-MCBS v1.1\nscore: 2; niraparib regardless of BRCA1/2-mut status:\nESMO-MCBS v1.1 score: 3; rucaparib regardless of\nBRCA1/2-mut status: ESMO-MCBS v1.1 score: 3].\n\u0004 For patients requiring rapid response, the combination\nof a platinum-based doublet (PLD, gemcitabine or pacli-\ntaxel) with bevacizumab is preferred [V, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3].",
    "metadata": {
      "rank": 3,
      "score": 0.6316000819206238
    },
    "cached_at": "2026-01-19T08:46:02.359722"
  },
  "nccn_ovariancancer_v3_2025__v00000000|15": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 15,
    "text": "n See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ndd Validated molecular testing should be performed in a CLIA-approved facility using the\nmost recent available tumor tissue. Tumor molecular analysis is recommended to include,\nat a minimum, tests to identify potential benefit from targeted therapeutics that have tumor-\nspecific or tumor-agnostic benefit including, but not limited to, HER2 status (by IHC),\nBRCA1/2, HRD status, MSI, MMR, TMB, BRAF, FRα (FOLR1), RET, and NTRK if prior\ntesting did not include these markers. More comprehensive testing may be particularly\nimportant in LCOC with limited approved therapeutic options (OV-B).\nee Tumor molecular testing prior to initiation of therapy for persistent/recurrent disease, if not\npreviously done.\nff Definitions of platinum-sensitive and platinum-resistant disease represent a spectrum of\ndisease; clinical judgment and flexibility should be utilized in determining treatment options.\nCombination platinum-\nbased chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive",
    "metadata": {
      "rank": 5,
      "score": 0.6245894432067871
    },
    "cached_at": "2026-01-19T08:46:02.362165"
  },
  "nccn_ovariancancer_v3_2025__v00000000|14": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 14,
    "text": "ff Definitions of platinum-sensitive and platinum-resistant disease\nrepresent a spectrum of disease; clinical judgment and flexibility should\nbe utilized in determining treatment options.\ngg Data are limited on primary and maintenance therapy for recurrent/\npersistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated\nas indicated with tumor markers and repeat imaging (with modalities\npreviously used) to document response and/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\njj Patients who do not respond and progress on two consecutive regimens\nwithout evidence of clinical benefits have diminished likelihood of\nbenefitting from additional therapy (Griffiths RW, et al. Int J Gynecol\nCancer 2011;21:58-65). Decisions to offer clinical trials, supportive care,\nor additional therapy should be made on an individual basis.\nkk Localized radiation therapy (RT) can be considered to palliate\nsymptoms and/or for oligometastatic disease.\nOV-8\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.",
    "metadata": {
      "rank": 4,
      "score": 0.6308409571647644
    },
    "cached_at": "2026-01-19T08:46:02.361002"
  },
  "esmo_cpg_epithelialovarian_2023__v00000000|4": {
    "doc_id": "esmo_cpg_epithelialovarian_2023__v00000000",
    "page": 4,
    "text": "procedures.20\nSystemic therapy\nAdjuvant platinum-based ChT signiﬁcantly prolongs OS and\nPFS in patients with early-stage EOC, as demonstrated in\nthe joint analysis of ACTION and ICON1 trials and a\nFigure 1. Management of early EOC (FIGO stage I-II).\nSee Supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2023.07.011, for a summary of the beneﬁt of adjuvant systemic therapy for early EOC (FIGO\nI-II stage).\nPurple: general categories or stratiﬁcation; red: surgery; blue: systemic anticancer therapy; white: other aspects of management; dashed lines: optional therapy.\nCCC, clear-cell carcinoma; ChT, chemotherapy; EC, endometrioid carcinoma; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics;\nHGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma; MC, mucinous carcinoma.\nAnnals of Oncology\nA. González-Martín et al.\n836\nhttps://doi.org/10.1016/j.annonc.2023.07.011\nVolume 34",
    "metadata": {
      "rank": 2,
      "score": 0.6608379483222961
    },
    "cached_at": "2026-01-19T05:31:04.140865"
  },
  "nccn_ovariancancer_v3_2025__v00000000|22": {
    "doc_id": "nccn_ovariancancer_v3_2025__v00000000",
    "page": 22,
    "text": "Survivorship)\nRecurrent\ndiseaset\nHormonal therapyu\nor\nChemotherapy (if not previously used), see OV-C (6 of 12)\nor\nSystemic therapyf,v\n• For platinum-sensitive disease, see OV-C (8 of 12)\n• For platinum-resistant disease, see OV-C (9 of 12)\nor\nObservation\nf See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions\n(OV-D).\no Validated molecular testing should be performed in a CLIA-approved facility\nusing the most recent available tumor tissue. Tumor molecular analysis is\nrecommended to include, at a minimum, tests to identify potential benefit from\ntargeted therapeutics that have tumor-specific or tumor-agnostic benefit including,\nbut not limited to, HER2 status (by IHC), BRCA1/2, HRD status, MSI, MMR,\nTMB, BRAF, FRα (FOLR1), RET, and NTRK if prior testing did not include these\nmarkers. More comprehensive testing may be particularly important in LCOC with\nlimited approved therapeutic options (OV-B).\np CT is performed with oral and iodinated IV contrast (unless contraindicated due\nto anaphylaxis or significant renal dysfunction) with or without rectal contrast. MRI\nis performed with gadolinium-based contrast agents (unless contraindicated due",
    "metadata": {
      "rank": 4,
      "score": 0.6561352610588074
    },
    "cached_at": "2026-01-19T08:37:13.532192"
  },
  "esmo_cpg_epithelialovarian_2023__v00000000|7": {
    "doc_id": "esmo_cpg_epithelialovarian_2023__v00000000",
    "page": 7,
    "text": "A descriptive OS analysis of SOLO1 at 7-year follow-up60\nand the ﬁnal OS analysis of PAOLA-161 have shown a beneﬁt\nin OS for olaparib in patients with BRCA1/2-mutated tu-\nmours and olaparibebevacizumab in patients with HRD-\npositive tumours regardless of BRCA1/2-mut status (see\nSupplementary Material Section 3, available at https://doi.\norg/10.1016/j.annonc.2023.07.011).\nNon-high-grade serous advanced ovarian cancer. Pacli-\ntaxelecarboplatin is the standard systemic ChT used in\nLGSC, CCC and MC. Multiple retrospective studies, however,\nshowed lower response rates in these histotypes compared\nwith HGSC.62-64 Bevacizumab has shown activity in all his-\ntotypes including those less chemoresponsive, e.g. LGSC or\nCCC.49 The majority of LGSCs have high expression of es-\ntrogen receptor (ER) and progesterone receptor (PgR);\nretrospective studies suggest a possible therapeutic value of\nhormone therapy in the maintenance of newly diagnosed\nadvanced LGSC.65 This intervention is currently under\nevaluation in a prospective RCT (NCT04095364).\nRecommendations\n\u0004 Patients with advanced EOC should be evaluated for PCS\nby a specialised team, with the aim of achieving",
    "metadata": {
      "rank": 5,
      "score": 0.6144667267799377
    },
    "cached_at": "2026-01-19T06:58:48.805009"
  },
  "esgo_esmo_esp_consensus_ovariancancer_2024__v00000000|10": {
    "doc_id": "esgo_esmo_esp_consensus_ovariancancer_2024__v00000000",
    "page": 10,
    "text": "platinum-based ChT followed by niraparib or rucaparib if\nin CR/PR/NED [I, B].\nConsensus: 97% (35) yes, 0% (0) no, 3% (1) abstain (36\nvoters)\nRecommendation 13.9: When used as maintenance in\npatients in CR/PR/NED to platinum-based ChT, olaparib\n(alone or in combination with bevacizumab) and rucaparib\nare recommended for 2 years, and niraparib is recom-\nmended for 3 years [I, A].\nConsensus: 97% (34) yes, 0% (0) no, 3% (1) abstain (35\nvoters)\n14. How should older/frail patients with tubo-ovarian\ncarcinoma be investigated and treated?\nOlder patients are under-represented in clinical trials due\nto their poor performance status (PS) and comorbidities,88\nand their outcomes are poorer.89 Geriatric assessment\ngathers information on functional, mental and nutritional\nstatus, emotional conditions and social support.90 Vulner-\nability scores have been validated in clinical trials.90,91\nSurgery, frequently carried out in an emergency context\nand in unspecialised centres, is often incomplete, with\nhigher\npost-operative\ncomplications.92\nChT\nmay\nbe\nunderutilised.93,94\nRecommendation 14.1: Patients should not be excluded\nfrom diagnostic procedures, clinical trials and speciﬁc",
    "metadata": {
      "rank": 5,
      "score": 0.6232171654701233
    },
    "cached_at": "2026-01-19T08:00:34.696914"
  },
  "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000|17": {
    "doc_id": "esgo_eshre_esge_fertilitysparing_pocket_2025__v00000000",
    "page": 17,
    "text": "17\nTable 1\nIndications for in vivo ovarian tissue preservation in ovarian\nneoplasms according to the histological type and the stage\nof the disease\nSTAGE\nEPITHELIAL OVARIAN NEOPLASMS\nNON-EPITHELIAL OVARIAN NEOPLASMS\nBOT1\nLGSC\nLGEC\nMCexp\nCCC\nHGSC\nHGEC\nMCinf\nGCT2\nSCC\nGrCT\nSLCT3\nSLCT4\nIA\nIB\nIC1\nIC2\n##\nIC3\n##\nII-IV\n#\n\nfavourable oncologic selection criteria for fertility-sparing management as defined in\nthe text (based on the favourable survival and/or recurrence rates observed in cohorts and/\nor comparative studies (radical versus conservative) of patients treated with such characteris-\ntics).\n\noncologic selection criteria acceptable in selected cases (insufficient or conflicting data\nto evaluate accurately the results of the ovarian preservation in this subgroup of patients).\n\nunfavourable oncologic selection criteria for ovarian preservation (poorest survival\nobserved in patients having an ovarian preservation in these subgroups. It could be related\nto the use of ovarian preservation itself and/or the natural history of the disease (whatever\nthe preservation or not of the ovary) in these patients having poorest prognostic factors).",
    "metadata": {
      "rank": 3,
      "score": 0.6259449124336243
    },
    "cached_at": "2026-01-19T08:27:01.047825"
  },
  "esmo_cpg_nonepithelialovarian_2018__v00000000|13": {
    "doc_id": "esmo_cpg_nonepithelialovarian_2018__v00000000",
    "page": 13,
    "text": "nately, none of them has been compared with BEP in randomised\ntrials. A phase II Gynecologic Oncology Group (GOG) trial\nreported high activity with an acceptable toxicity proﬁle for a\ncarboplatin–etoposide combination in the adjuvant setting\nof completely resected stages I–III dysgerminomas [40].\nDysgerminomas are very sensitive to RT; however, its use is lim-\nited to selected cases because of the negative impact on fertility.\nIn patients with platinum-sensitive relapse (progression\n> 4–6 weeks after completion of ChT), ifosfamide/platinum (IP)\nwith or without paclitaxel (P) should be considered as second-\nline treatment [IV, C] [41]. Further active ChT regimens include:\nvinblastine/ifosfamide/cisplatin (VeIP) and cisplatin/vinblastine/\nbleomycin (PVB) [IV, C] [42]. Patients resistant to a cisplatin-\nbased combination may receive vincristine/actinomycin D/cyclo-\nphosphamide (VAC) or paclitaxel/gemcitabine or gemcitabine/\noxaliplatin as salvage therapy [IV, C].\nAlthough there is a role for ASCT in relapsed testicular cancer, it\nis not the standard of care for women with relapsed or recurrent\nmalignant ovarian GCTs and its role remains undeﬁned because of",
    "metadata": {
      "rank": 4,
      "score": 0.6247340440750122
    },
    "cached_at": "2026-01-19T08:27:01.049371"
  }
}